Group 1 - Neogen reported quarterly earnings of $0.11 per share, matching the Zacks Consensus Estimate, and the same as the previous year [1] - The company posted revenues of $231.26 million for the quarter ended November 2024, exceeding the Zacks Consensus Estimate by 2.16% and showing a slight increase from $229.63 million a year ago [2] - Neogen shares have increased approximately 7.7% since the beginning of the year, outperforming the S&P 500's gain of 0.6% [3] Group 2 - The earnings outlook for Neogen is uncertain, with current consensus EPS estimates at $0.15 for the coming quarter and $0.51 for the current fiscal year [7] - The estimate revisions trend for Neogen is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Products industry, to which Neogen belongs, is ranked in the bottom 44% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]
Neogen (NEOG) Q2 Earnings Match Estimates